Revance Therapeutics, Inc. (RVNC)

Number of records: 50
SEC FilingInsiderCompanyTrade DateTransactionSharesAvg. PriceTotal% HoldingsReturn
27-Jul-20 7:57 PM
View: 
Rankin Aubrey
President, Innovation & Tech
Director
Revance Therapeutics, Inc. (RVNC) 23-Jul-20Grant 667,292----255%
261.45K to 928.75K
02-Jul-20 8:20 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 30-Jun-20Acquisition (other) 1,000$13.80$13,795.503%
33.06K to 34.06K
02-Jul-20 8:18 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 30-Jun-20Acquisition (other) 763$13.80$10,526.002%
38.8K to 39.56K
15-May-20 6:41 PM
View: 
Nolet Chris
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----67%
9.0K to 15.0K
15-May-20 6:45 PM
View: 
Beraud Jill
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----67%
9.0K to 15.0K
15-May-20 6:42 PM
View: 
Vickers Philip J.
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----44%
13.65K to 19.65K
15-May-20 6:39 PM
View: 
Gardner Phyllis
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----57%
10.5K to 16.5K
15-May-20 6:34 PM
View: 
Russell Angus C.
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----57%
10.5K to 16.5K
15-May-20 6:33 PM
View: 
Gangolli Julian S
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----57%
10.5K to 16.5K
15-May-20 6:35 PM
View: 
Byrnes Robert F
Director
Revance Therapeutics, Inc. (RVNC) 14-May-20Grant 6,000----25%
24.16K to 30.16K
17-Apr-20 7:51 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 15-Apr-20Payment of Exercise 432$14.80$6,393.60(1%)
33.5K to 33.06K
17-Mar-20 8:34 PM
View: 
Joshi Abhay
COO, President of R&D
Revance Therapeutics, Inc. (RVNC) 15-Mar-20Payment of Exercise 1,354$15.50$20,987.00(1%)
103.19K to 101.83K
19-Feb-20 8:18 PM
View: 
Moxie Dwight
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 18-Feb-20Grant 25,000----100%
0 to 25.0K
19-Feb-20 8:20 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 15-Feb-20Payment of Exercise 288$25.33$7,295.04(< 1%)
33.78K to 33.5K
19-Feb-20 8:22 PM
View: 
Joshi Abhay
COO, President, R&D
Revance Therapeutics, Inc. (RVNC) 15-Feb-20Payment of Exercise 3,325$25.33$84,222.20(3%)
106.51K to 103.19K
19-Feb-20 8:21 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 15-Feb-20Payment of Exercise 576$25.33$14,590.10(1%)
39.37K to 38.8K
19-Feb-20 8:23 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 15-Feb-20Payment of Exercise 864$25.33$21,885.10(4%)
24.32K to 23.45K
24-Jan-20 8:18 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 23-Jan-20Grant 20,000----145%
13.78K to 33.78K
24-Jan-20 8:21 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 23-Jan-20Grant 16,500----72%
22.87K to 39.37K
24-Jan-20 8:16 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 23-Jan-20Grant 25,000----31%
81.51K to 106.51K
24-Jan-20 8:22 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 23-Jan-20Grant 200,000----94%
213.5K to 413.5K
17-Jan-20 8:12 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 15-Jan-20Payment of Exercise 4,441$22.89$101,654.00(5%)
85.95K to 81.51K
03-Jan-20 6:42 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 31-Dec-19Acquisition (other) 504$10.82$5,453.282%
22.37K to 22.87K
1%
03-Jan-20 6:46 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 31-Dec-19Acquisition (other) 382$10.82$4,133.242%
23.93K to 24.32K
1%
03-Jan-20 6:48 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 31-Dec-19Acquisition (other) 382$10.82$4,133.243%
13.4K to 13.78K
1%
17-Dec-19 8:00 PM
View: 
Sjuts Dustin S
Chief Commercial Officer
Revance Therapeutics, Inc. (RVNC) 15-Dec-19Payment of Exercise 576$15.99$9,210.24(5%)
12.07K to 11.49K
17-Dec-19 7:57 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 15-Dec-19Payment of Exercise 1,556$15.99$24,880.40(7%)
23.92K to 22.37K
17-Dec-19 7:56 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 14-Dec-19Payment of Exercise 2,971$15.99$47,506.30(3%)
88.92K to 85.95K
15-Oct-19 8:23 PM
View: 
Foley Mark J
CEO & President
Director
Revance Therapeutics, Inc. (RVNC) 13-Oct-19Grant 200,000----597%
33.5K to 233.5K
18-Jul-19 8:29 PM
View: 
Nolet Chris
Director
Revance Therapeutics, Inc. (RVNC) 16-Jul-19Grant 9,000----100%
0 to 9.0K
02-Jul-19 9:14 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 28-Jun-19Acquisition (other) 1,000$11.02$11,024.504%
22.93K to 23.93K
(< 1%)
02-Jul-19 9:16 PM
View: 
Schilke Tobin
CFO
Revance Therapeutics, Inc. (RVNC) 28-Jun-19Acquisition (other) 923$11.02$10,175.604%
23.0K to 23.92K
(< 1%)
02-Jul-19 9:15 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 28-Jun-19Acquisition (other) 1,000$11.02$11,024.50< 1%
151.6K to 152.6K
(< 1%)
17-Jun-19 8:30 PM
View: 
McDowell Caryn Gordon
SVP, GC & Secretary
Revance Therapeutics, Inc. (RVNC) 15-Jun-19Payment of Exercise 1,383$10.86$15,019.40(6%)
24.32K to 22.93K
(1%)
06-Jun-19 7:34 PM
View: 
Beraud Jill
Director
Revance Therapeutics, Inc. (RVNC) 04-Jun-19Grant 9,000----100%
0 to 9.0K
10-May-19 9:11 PM
View: 
Vickers Philip J.
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----49%
9.15K to 13.65K
10-May-19 8:52 PM
View: 
Foley Mark J
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----16%
29.0K to 33.5K
10-May-19 9:05 PM
View: 
Gardner Phyllis
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----75%
6.0K to 10.5K
10-May-19 9:09 PM
View: 
Russell Angus C.
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----75%
6.0K to 10.5K
10-May-19 8:54 PM
View: 
Gangolli Julian S
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----75%
6.0K to 10.5K
10-May-19 8:49 PM
View: 
Byrnes Robert F
Director
Revance Therapeutics, Inc. (RVNC) 09-May-19Grant 4,500----23%
19.66K to 24.16K
19-Mar-19 9:01 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 18-Mar-19Market Sale (Planned) 11,613$15.51$180,068.00(7%)
163.22K to 151.6K
(3%)
19-Mar-19 8:58 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 18-Mar-19Market Sale (Planned) 498$15.48$7,709.04(7%)
6.9K to 6.4K
(3%)
19-Mar-19 9:01 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 15-Mar-19Payment of Exercise 6,137$15.45$94,816.60(4%)
169.35K to 163.22K
(4%)
18-Mar-19 8:34 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 15-Mar-19Payment of Exercise 1,354$15.45$20,919.30(1%)
90.28K to 88.92K
19-Mar-19 8:58 PM
View: 
Allouche Cyril
Principal Accounting Officer
Revance Therapeutics, Inc. (RVNC) 15-Mar-19Payment of Exercise 252$15.45$3,893.40(4%)
7.15K to 6.9K
(4%)
18-Mar-19 8:34 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 14-Mar-19Option Exercise 666$4.20$2,797.20< 1%
89.78K to 90.44K
18-Mar-19 8:34 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 14-Mar-19Payment of Exercise 166$15.59$2,587.94(< 1%)
90.44K to 90.28K
20-Feb-19 9:31 PM
View: 
Browne L Daniel
CEO and President
Director
Revance Therapeutics, Inc. (RVNC) 19-Feb-19Market Sale (Planned) 5,446$17.68$96,285.30(3%)
174.8K to 169.35K
< 1%
20-Feb-19 9:33 PM
View: 
Joshi Abhay
Chief Operating Officer
Revance Therapeutics, Inc. (RVNC) 15-Feb-19Payment of Exercise 1,510$17.69$26,711.90(2%)
91.29K to 89.78K
< 1%